Oxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug

London, UK

–News Direct–

OCTHF), entitled “Phase 1 approval for lead chronic pain drug.” Oxford Cannabinoid Technologies Holdings CEO Clarissa Sowemimo-Coker recently told Proactive’s Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.”>

Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a research note on Oxford Cannabinoid Technologies Holdings PLC ((LSE:OCTP, OTCQB:OCTHF), entitled “Phase 1 approval for lead chronic pain drug.” Oxford Cannabinoid Technologies Holdings CEO Clarissa Sowemimo-Coker recently told Proactive’s Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/oxford-cannabinoid-technologies-phase-1-approval-for-lead-chronic-pain-drug-570885289

2023 News Direct Corp.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *